Biocon plans $150-million capex in two years

Biocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 million to generics. Fueled by strong generics growth and biosimilar progress, Q4 net profit surged 153%. The company launched key medications in the US and UK, focusing on peptide portfolios and biosimilars for future growth, with analysts maintaining a positive outlook.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WvP9ASY
via IFTTT